

Yoh Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7894474/publications.pdf>

Version: 2024-02-01

18
papers

273
citations

1307594

7
h-index

996975

15
g-index

19
all docs

19
docs citations

19
times ranked

485
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-152 Regulates Endometrial Serous Carcinoma Cell Motility by Suppressing Matrix Metalloproteinase 10 Expression. <i>Tohoku Journal of Experimental Medicine</i> , 2022, 256, 249-258.	1.2	1
2	Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2). <i>PLoS ONE</i> , 2021, 16, e0236907.	2.5	7
3	The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2123-2129.	2.2	1
4	Association of g BRCA1/2 mutation locations with ovarian cancer risk in Japanese patients from the CHARLOTTE study. <i>Cancer Science</i> , 2020, 111, 3350-3358.	3.9	7
5	MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 263-272.	1.2	4
6	Abdominal Total Hysterectomy: The Modified Aldridge's Procedure with Noda's Method. <i>The Surgery Journal</i> , 2019, 05, S22-S26.	0.7	0
7	The first Japanese nationwide multicenter study of <i>BRCA</i> mutation testing in ovarian cancer: CHARacterizing the cross-sectional approach to Ovarian cancer geneTic TEsting of <i>BRCA</i> (CHARLOTTE). <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1043-1049.	2.5	80
8	Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial. <i>Gynecologic Oncology</i> , 2019, 155, 413-419.	1.4	6
9	Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression. <i>JAMA Oncology</i> , 2019, 5, 833.	7.1	45
10	Diagnostic value of combination serum assay of lactate dehydrogenase, Dâ€dimer, and Câ€reactive protein for uterine leiomyosarcoma. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 189-194.	1.3	19
11	Laparoscopic surgery for subserosal leiomyoma torsion in the acute and chronic phases: A report of three cases. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2019, 35, 123-130.	0.0	0
12	Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IBâ€IIB cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e11.	2.2	34
13	Clinicopathologic features and<i>BRCA</i> mutations in primary fallopian tube cancer in Japanese women. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 794-798.	1.3	5
14	Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey. <i>International Journal of Clinical Oncology</i> , 2017, 22, 541-547.	2.2	2
15	Primary osteosarcoma of the uterine cervix: A case report. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1781-1783.	1.3	3
16	Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group. <i>Gynecologic Oncology</i> , 2016, 141, 447-453.	1.4	16
17	Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. <i>International Journal of Clinical Oncology</i> , 2016, 21, 168-176.	2.2	42
18	Optimal debulking surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5591-5591.	1.6	1